PharmaCyte Biotech

PharmaCyte Biotech EPS

The Earnings per Share (EPS) of PharmaCyte Biotech (PMCB) as of Nov 16, 2026 is -1.81 USD. In the previous year, Earnings per Share (EPS) was 4.51 USD — a change of -140.11% (lower).

EPS

-1.81USD

YoY

-140.11%

Last updated:

Earnings per Share (EPS) of PharmaCyte Biotech is 2026 -1.81 USD. Earnings per Share (EPS) of PharmaCyte Biotech was 2025 4.51 USD. It decreases by -140.11% lower compared to the previous year.

The PharmaCyte Biotech EPS history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EPS
Date
EPS
Jan 1, 2019
-4.60 USD
Jan 1, 2020
-2.49 USD
Jan 1, 2021
-0.20 USD
Jan 1, 2022
-0.21 USD
Jan 1, 2023
-0.49 USD
Jan 1, 2024
0.04 USD
Jan 1, 2025
4.51 USD
Jan 1, 2026
-1.81 USD
The PharmaCyte Biotech EPS history
YEAREPSYoY
-1.81USD-140.11%
4.51USD+10,221.91%
0.04USD-108.88%
-0.49USD+139.11%
-0.21USD+0.65%
-0.20USD-91.77%
-2.49USD-46.01%
-4.60USD-51.42%
-9.48USD+38.38%
-6.85USD-36.07%
-10.71USD-50.96%
-21.85USD-62.42%
-58.12USD+1,212.24%
-4.43USD-99.93%
-6,331.04USD+112,912.54%
-5.60USD-78.27%
-25.78USD-31.36%
-37.56USD+44.13%
-26.06USD-21.19%
-33.07USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

PharmaCyte Biotech Stock analysis

What does PharmaCyte Biotech do? PharmaCyte Biotech, Inc. develops treatments for cancer and diabetes using its Cell-in-a-Box technology platform. The company focuses on encapsulating live cells to deliver cancer-killing drugs directly to tumor sites for advanced, inoperable pancreatic cancer and other solid tumors. It also develops a therapy for Type I and insulin-dependent Type II diabetes by encapsulating genetically engineered human cells that produce insulin in response to blood sugar levels. PharmaCyte Biotech generates revenue through the development and potential commercialization of these therapies, targeting clinical-stage biotechnology markets with specialized treatment approaches. The company's Cell-in-a-Box technology serves as the foundation for both cancer and diabetes therapies, enabling targeted drug delivery and insulin production. PharmaCyte Biotech's clinical-stage development pipeline includes treatments for pancreatic cancer and diabetes, with no mention of additional products or brands. Revenue would come from future partnerships, licensing agreements, or product sales once therapies reach commercialization, though current operations are focused on research and development. PharmaCyte Biotech operates with a small team of four full-time employees, indicating a lean operational structure focused on research rather than sales. The company's business model relies on advancing its technology through clinical trials to attract potential partners or buyers, with no indication of current revenue streams beyond development activities. Its primary market segments are patients with advanced pancreatic cancer and insulin-dependent diabetes, though these are not yet commercialized products. PharmaCyte Biotech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about PharmaCyte Biotech stock

Earnings per Share (EPS) of PharmaCyte Biotech is -1.81 USD in 2026.

Earnings per Share (EPS) of PharmaCyte Biotech changed from 4.51 USD to -1.81 USD, representing a -140.11% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Earnings per Share (EPS) PharmaCyte Biotech since 2006 – with annual values, charts, and detailed analysis.

Earnings per Share measures the portion of a company's profit allocated to each outstanding share. It is a key metric for assessing a company's profitability on a per-share basis.

EPS = Net Income / Shares Outstanding

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — PharmaCyte Biotech

All Key Metrics — PharmaCyte Biotech